GCP
SCPH

GSA Capital Partners’s scPharmaceuticals SCPH Stock Holding History

GSA Capital Partners’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-22,609
Closed -$230K – 1856
2023
Q2 		$230K Buy
+22,609
New +$236K 0.02% 1192

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return

GSA Capital Partners's SCPH Position: Q3 2023 in Review

GSA Capital Partners sold out of scPharmaceuticals (SCPH) in Q3 2023, closing a stake of 22,609 shares — an estimated $230K sold.

GSA Capital Partners first reported a position in SCPH in Q2 2023 and held it in 1 quarter. The position peaked at $230K in Q2 2023. 73 funds tracked by Wall St. Rank hold SCPH as of Q3 2023.

  • GSA Capital Partners reported no remaining scPharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • GSA Capital Partners sold 22,609 scPharmaceuticals shares in Q3 2023, an estimated $230K.
  • GSA Capital Partners first reported a position in scPharmaceuticals in Q2 2023 and held it in 1 quarter.
  • GSA Capital Partners's scPharmaceuticals position peaked at $230K in Q2 2023.
  • 73 funds tracked by Wall St. Rank held scPharmaceuticals as of Q3 2023.

Based on GSA Capital Partners's 13F filing for Q3 2023, filed 15 Nov 2023.